Germany

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CFRT 2020

Participation Not Confirmed

Update your events

U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children

Lead Product(s): Nifurtimox

Therapeutic Area: Infections and Infectious Diseases Product Name: Lampit

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 07, 2020

Details:

U.S FDA has approved Lampit® (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi (T. cruzi).

MYR Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CFRT 2020

Participation Not Confirmed

Update your events

MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®

Lead Product(s): Bulevirtide

Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 04, 2020

Details:

HEPCLUDEX® has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe.

AiCuris

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CFRT 2020

Participation Not Confirmed

Update your events

Royalty Pharma Acquires Partial Royalty Interest On Prevymis™ (Letermovir) From Aicuris Anti-Infective Cures Gmbh

Lead Product(s): Letermovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Royalty Pharma

Deal Size: $220.0 million Upfront Cash: $220.0 million

Deal Type: Acquisition June 09, 2020

Details:

Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high risk for CMV reactivation.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Bayer HealthCare

U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children

MYR Pharmaceuticals

MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®

AiCuris

Royalty Pharma Acquires Partial Royalty Interest On Prevymis™ (Letermovir) From Aicuris Anti-Infective Cures Gmbh